Irie J, Inagaki E, Fujita M, et al. Safety and efficacy of nicotinamide mononucleotide (NMN) in healthy subjects: a randomized, double-blind, placebo-controlled study. Endocr J. 2022;69(3):243-256.

Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized controlled trial. J Int Soc Sports Nutr. 2021;18(1):47.

Yoshino J, Mills KF, Yoon MJ, Imai S-I. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.

de Guia RM, et al. Nicotinamide mononucleotide supplementation in humans: current clinical evidence and future directions. Front Aging. 2023;4:XXXX. (systematic review)

Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence.Cell Metab. 2018;27(3):529-547.

Castro-Marrero J, Sáez-Francàs N, Segundo MJ, et al. Coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation improves fatigue and quality of life in chronic fatigue syndrome. Antioxid Redox Signal.2022;36(6):416-426.

Formentini L, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Nutrients. 2023;15(22):4882. PMID: 37971292.

Grant R, Berg J, Mestayer R, et al. Administration of NAD⁺ increases circulating NAD⁺ metabolites in humans. Front Aging Neurosci. 2019;11:284.

Demarin V, Podobnik SS, et al. Nicotinamide adenine dinucleotide (NADH) in the treatment of cognitive impairment and Alzheimer’s disease. Arch Phys Med Rehabil. 2022;103(1):e12. https://www.archives-pmr.org/article/S0003-9993(21)01109-6/abstract

Brakedal B, Dolle C, et al. NADPARK: Nicotinamide riboside improves cerebral NAD metabolism in Parkinson’s disease. Cell Metab. 2022;34(7):1078-1089.e6.